Substitute for for	m 1449A/PTO			Co	Complete if Known				
	·····			Application Number	10/544,146				
	ATION DISCI ENT BY APP			Filing Date	May 5, 2006				
STATEME	ENTBYAPP	LIC	ANI	First Named Inventor	Shyam S. Mohapatra				
(u.	se as many sheets	as nec	cessary)	Art Unit	1635				
				Examiner Name	Richard A. Schnizer				
Sheet	1	of	5	Attorney Docket Number	USF.T193XC1				

			U.S. PATENT DO	OCUMENTS	
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2004/0002458 A1	01-01-2004	Seilhamer et al.	All
	U2	US-2005/0266093 A1	12-01-2005	Mohapatra	All
	U3	US-2005/0272650 A1	12-08-2005	Mohapatra	All
	U4	US-2006/0276382 A1	12-07-2006	Mohapatra	All
	U5	US-2007/0265204 A1	11-15-2007	Mohapatra et al.	All
	U6 US-2007/0116767 A1 05-24		05-24-2007	Mohapatra	All
	U7	US-2007/0009951 A1	01-11-2007	Mohapatra et al.	All
	U8	US-2008/0023325 A1	01-31-2008	Mohapatra et al.	All

		FOREIGN	PATENT DOCU	JMENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Document  Country Code 3 - Number 4- Kind Code5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pessages or Relevant Figures Appear	T.
	F1	WO 2003/028759 A1	04-10-2003	University of South Florida et al.	All	
	F2	WO 2003/070918 A2	08-28-2003	Ribozyme Pharmaceuticals, Incorporated	All	
	F3	WO 2003/092618 A2	11-13-2003	University of South Florida	All	
	F4	WO 2004/074314 A2	08-02-2004	University of South Florida	All	
	F5	WO 2004/076664 A2	09-10-2004	University of South Florida	All	
	F6	WO 2005/094420 A2	10-13-2005	University of South Florida	All	
	F7	WO 2005/105136 A1	11-10-2005	University of South Florida	All	

Signature	Considered	
*EXAMINER: Initial if reference considered, w considered. Include copy of this form with ne.	thether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not xt communication to applicant. *Applicant's unique citation designation number (optional) * See Kind Codes of	

considered. Include copy of this form with next communication to applicant. \*Applicant's unique orlation designation number (options): \*See Kind Coyles of USFTO Patient Documents at <a href="https://www.usplo.gogy">www.usplo.gogy</a> or MPEP90104. \*Berter Office that issued the document, by the two-letter code (WIPO Sandard T.5): \*For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document. \*Kind of document by the appropriate symbols as an indicated on the document under WIPO Sandard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is studied.

This collection of information is required by 3 T CPR 1.97 and 1.98. The information is noused to obtain or retain a benefit by the public which is to file qund by the USFTO to proceed an application. Conditionable to generate by 35 U.S.C. 122 and 3 CFR 1.14. This collection is estimated by 2-burst b complexi-including pathering preparing, and submitting the completed application form to the USFTO. Then will vary depending upon the individual case. Any comments on the amount of time you require to complete this form andor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Peata and Trademark Office, P.O. Box 1450, Alexandria, W. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, W. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, W. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Examiner

Substitute for for	m 1449A/PTO				Con	Complete if Known				
INFORMA	TION DIOO!	~~:			Application Number	10/544,146				
	ATION DISCL ENT BY APP				Filing Date	May 5, 2006				
STATEME	ENIBIAPP	LICA	AIN I		First Named Inventor	Shyam S. Mohapatra				
(u	se as many sheets	as nec	essary)		Art Unit	1635				
					Examiner Name	Richard A. Schnizer				
Sheet 2 of				5	Attorney Docket Number	USF.T193XC1				

			U.S. PATENT DO	CUMENTS	
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U9	US-2008/0070858 A1	03-20-2008	Mohapatra	All
	U10	US-2008/0075731 A1	03-27-2008	Mohapatra et al.	All
	U11	US-2008/0100279 A1	05-01-2008	Mohapatra et al.	All
	U12	US-5,931,069	11-03-1998	Barik	All
	U13	US-5,998,602	12-07-1999	Torrence et al.	All
	U14	US-6,489,306	12-03-2002	Mohapatra et al.	All
	U15	US-6,900,299	05-31-2005	Mohapatra et al.	All
	U16	US-7,118,888	10-10-2006	Mohapatra et al.	All
	U17	US-2001/0006951 A1	07-05-2001	Mohapatra et al.	All
	U18	US-2008/0249057 A1	10-09-2008	Mohapatra et al.	All
	U19	US-5,290,540	03-01-1994	Prince et al.	All
	U20	US-5,693,532	12-02-1997	McSwiggen et al.	All
	U21	US-6,586,579	06-01-2003	Huang et al.	All
	U22	US-7,354,908	04-08-2008	Mohapatra et al.	All

		FOREIGN	PATENT DOCU	JMENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Document  Country Code 3 - Number 4 - Kind Code <sup>6</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Pessages or Relevant Figures Appear	T <sup>c</sup>
	F8	WO 2007/127480 A2	11-08-2007	University of South Florida	All	
	F9	WO 2007/127487 A2	11-03-2007	University of South Florida	All	
	F10					
	F11					
	F12					

Examiner	Date	
Signature	Considered	

\*EXAMINER: nitial if reference considered, whether or not cliation is no conformance with MPEP 690. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant. "Applicant in quite citation designation number (policion) See Kind Codes of USFTO Patent Documents at www.upto.gov or MPEPP01.04. "Enter Office that issued the document, by the three-better code (WPO Sandard T.)." For Japanese patient documents, the includation of the year of the regind the Engineer must procedule sestial number of the patient document. "End of document up that appropriate symbols as indicated on the year of the regind the Engineer must procedule the sestial number of the patient document." End of document up that appropriate symbols as indicated on the document under WIPO Sandard ST. 16 if possible. "Applicant is to gleace a sched mark here if English linguings."

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to proceeds) an application. Confidentiality is gowened by 39 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to Pours to complete including agritering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of the you require to complete this form andor suggestions for reducing this burden, should be sent to the their individual case. Any comments and the amount of the you require to complete this form andor suggestions for reducing this burden, should be sent to the their individual case. Any comments and Trademark Office, P.O. Box 1450, Alexandria, VA. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 4450, Alexandria, VA. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## Complete if Known Substitute for form 1449B/PTO **Application Number** 10/544.146 INFORMATION DISCLOSURE Filing Date May 5, 2006 STATEMENT BY APPLICANT First Named Inventor Shyam S. Mohapatra Group Art Unit 1635 (use as many sheets as necessary) **Examiner Name** Richard A. Schnizer Sheet of Attorney Docket Number USF.T193XC1 3

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	R1	BEHERA, A.K. et al. 'Adenovirus-Mediated Interferon y Gene Therapy for Allergic Asthma: Involvement of Interleukin 12 and STAT4 Signaling' Human Gene Therapy, September 2002, 13:1697-1709.	
	R2	BEHERA, A.K. et al. "2-5" Oligoadenylate Synthetase Plays a Critical Role in Interferon-y Inhibition of Respiratory Syncytial Virus Infection of Human Epithelial Cells" The Journal of Biological Chemistry, July 2002, 277(28):25601-25608.	
	R3	BITKO, V. et al. "Phenotypic silencing of cytoplasmic genes using sequence-specific double- stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses" BMC Microbiology, 2001, 1(34):1-11.	
	R4	BOSSERT, B. et al. "Respiratory Syncytial Virus (RSV) Nonstructural (NS) Proteins as Host Range Determinants: a Chimeric Bovine RSV with NS Genes from Human RSV IS Attenuated in Interferon- Competent Bovine Cells' Journal of Virology, May 2002, 76(9):4287-4293.	
	R5	BOSSERT, B. et al. "Nonstructural Proteins NS1 and NS2 of Bovine Respiratory Syncytial Virus Block Activation of Interferon Regulatory Factor 3" Journal of Virology, August 2003, 77(16):8661-8668.	
	R6	DORN, G. et al. "siRNA relieves chronic neuropathic pain" Nucleic Acids Research, 2004, 32(5):e49.	
	R7	HALLAK, L.K. et al. "Iduronic Acid-Containing Glycosaminoglycans on Target Cells Are Required for Efficient Respiratory Syncytial Virus Infection" Virology, 2000, 271:264-275.	
	R8	HELLERMAN, G.R. et al. "Genetic therapy: on the brink of a new future" Genetic Vaccines and Therapy, 2003, 1(1):1-2.	
	R9	JAIRATH, S. et al. "Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides" Antiviral Research, 1997, 33:201-213.	
	R10	JIN, H. et al. "Recombinant Respiratory Syncytial Viruses with Deletions in the NS1, NS2, SH, and M2-2 Genes are Attenuated in Vitro and in Vivo" Virology, 2000, 273:210-218.	
	R11	KUMAR, M. et al. "Intranasal IFN-y gene transfer protects BALB/c mice against respiratory syncytial virus infection" Vaccine, 2000; 18:558-567.	
	R12	KUMAR, M. et al. "Intranasal Gene Transfer by Chitosan-DNA Nanospheres Protects BALB/c Mice Against Acute Respiratory Syncytial Virus Infection" Human Gene Therapy, August 2002, 13:1415- 1425.	
	R13	KUMAR, M. et al. "Chitosan IFN-y-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma" Genetic Vaccines and Therapy, 2003, 1(3):1-10.	

Examiner		Date	
Signature		Considered	
*EXAMINER: Initi	If reference considered, whether or not citation is in conformance with MPEP 60	9. Draw line the	rough citation if not in conformance
and not considered	Include copy of this form with next communication to applicant.		

Applicant's unique citation designation number (potional). Applicant is to jaice a check mark here if English language Translation is attached.
This collection of information is required by 30 FCR 14.8. The information is required to obtain or retain a benefit by the public which is to fie and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including attention, presenting, and submitting the completed application from the tus USPTO. Three will vary depending upon the individual case. The promisers of the amount of time you recuire to complete this form and/or suppessions for reducing this burden, should be sent to the Chell information Officer U.S. Patent and Commissioner for Patents, P.O. 60 COMPLETED PORMIS TO THIS ADDRESS. SERVI TO:
Commissioner for Patents, P.O. 60 v. 4550. Alexanders, V. 22331-4490.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## Complete if Known Substitute for form 1449B/PTO Application Number 10/544,146 INFORMATION DISCLOSURE Filing Date May 5, 2006 STATEMENT BY APPLICANT First Named Inventor Shyam S. Mohapatra Group Art Unit 1635 (use as many sheets as necessary) **Examiner Name** Richard A. Schnizer Sheet of 5 Attorney Docket Number USF T193XC1 4

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), titls of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R14	LEAMAN, D.W. et al. "Targeted Therapy of Respiratory Syncytial Virus in African Green Monkeys by Intranasally Administered 2-5A Antisense" Virology, 2002, 292:70-77.	
	R15	MATSUSE, H. et al. "Recurrent Respiratory Syncytial Virus Infections in Allergen-Sensitized Mice Lead to Persistent Airway Inflammation and Hyperresponsiveness" <i>The Journal of Immunology</i> , 2000, 164.6583-8592.	
	R16	MOHAPATRA, S. "Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus" The Pediatric Infectious Disease Journal, February 2003, 22(2):S100-S104.	Γ
	R17	MURPHY, B.R. "Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics" <i>The Journal of Clinical Investigation</i> , July 2002, 110(1):21-27.	
	R18	LAZAR, I. et al. "Human Metapneumovirus and Severity of Respiratory Syncytial Virus Disease" Emerging Infectious Diseases, July 2004, 10(7):1318-1320, NCBI accession no. M74568.	
	R19	DEPLANCHE, M. et al. "In vivo evidence for quasispecies distributions in the bovine respiratory syncytial virus genome" Journal of General Virology, 2007, 88:1260-1265, NCBI accession no. NC_001989.	
	R20	PAN, W. et al. "Isolation of virus-neutralizing RNAs from a large pool of random sequences" Proc. Natl. Acad. Sci. USA, December 1995, 92:11509-11513.	
	R21	SCHLENDER, J. et al. "Bovine Respiratory Syncytial Virus Nonstructural Proteins NS1 and NS2 Cooperatively Antagonize Alpha/Beta Interferon-Induced Antiviral Response' Journal of Virology, 2000, September 2000, 74(18):8234-8242.	
	R22	SOUTSCHEK, J. et al. "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs" Nature, November 2004, 432:173-178.	
	R23	SPANN, K.M. et al. "Suppression of the Induction of Alpha, Beta, and Gamma Interferons by the NS1 and NS2 Proteins of Human Respiratory Syncytial Virus in Human Epithelial Cells and Macrophages" Journal of Virology, April 2004, 78(6):4363-4369.	
	R24	STEIN, C.A. "The experimental use of antisense oligonucleotides: a guide for the perplexed" The Journal of Clinical Investigation, 2001, 108:641-644.	
	R25	TENG, M.N. et al. "Altered Growth Characteristics of Recombinant Respiratory Syncytial Viruses Which Do Not Produce NS2 Protein" Journal of Virology, January 1999, 73(1):468-473.	
	R26	TENG, M.N. et al. "Recombinant Respiratory Syncytial Virus That Does Not Express the NS1 or M2- 2 Protein Is Highly Attenuated and Immunogenic in Chimpanzees" <i>Journal of Virology</i> , October 2000, 74(19):9317-9321.	

1	Examiner												Date				- 1
	Signature											1	Considered				J
	*EXAMINER:	Initial it	reference	considered	whether	or not	citation	is in	conformance	with	MPEP 6	809	Draw line for	nuch citation	if not	n conforms	nce

and not considered include copy of this form with next communication to applicant.

Applicant is unused uclaimor designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is eliminated to take 2 host process has applicated for the complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Other Information (CIV. U.S. Paleert and Trademark Office, P.O. Box 1450, Alexandria, VA. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Palents, P.O. Box 1450, Alexandria, VA. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## Substitute for form 1449B/PTO INFORMATION DISCLOSURE

Sheet

STATEMENT BY APPLICANT

(use as many sheets as necessary)

5 of 5

Complete if Known			
Application Number 10/544,146			
Filing Date	May 5, 2006 Shyam S. Mohapatra		
First Named Inventor			
Group Art Unit	1635		
Examiner Name	Richard A. Schnizer		
Attorney Docket Number USF.T193XC1			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, dily and/or country where published.	Т		
	R27	ZHANG, W. et al. "Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery" Genetic Vaccines and Therapy, 2004, 2(8):1-10.	Γ		
	R28	ZHANG, X. et al. "Small Interfering RNA Targeting Heme Oxygenase-1 Enhances Ischemia- Reperfusion-Induced Lung Apoptosis" The Journal of Biological Chemistry, March 2004, 279(11):10877-10884.	Γ		
	R29	ZHAO, C.A. et al. "Inhibition of respiratory syncytial virus replication in cultured cells by RNA-cleaving DNAzyme" Chinese Journal of Pediatrics, 2003, 41(8): 594-597, Medline XP002513933 Database accession No. NLM14744382.	Ī		
	R30	REICH, S.J. et al. "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model" Molecular Vision, 2003, 9:210-216.			
	R31	SUBRAMANYA, S. et al. "Targeted Delivery of Small Interfering RNA to Human Dendritic Cells to Suppress Dengue Virus Infection and Associated Proinflammatory Cytokine Production" Journal of Virology, March 2010, 84(5):2490-2501.	Ī		
	R32				
	R33				
	R34		L		
	R35		L		
	R36		L		
	R37		L		
	R38		L		

Examiner Signature	/Richard Schnizer/	Date Considered	04/07/2010
Signature		Considered	01.07.2010

"EXAMINER: Initial if reference considered, whether or not clation is in conformance with MPEP 609. Draw line through clation if not in conformance and not considered, include copy of this form with next communication to applica and hot when the result in the conformance and not considered include copy of this form with next communication to applica and hot mark here if English language Translation is afficient (Applican's unique clation designation number (optional). "Applican's to place and hot mark here if English language Translation is that the language Translation is afficient to a serious control of the conformation is required by 3° CRT 1.98." I'm information is required to obtain or retain a benefit by the public which is to the (and by the USPTO

This collection of information is required by 37 CFR 1.88. The information is required to optain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C. 123 and 37 CFR 1.14. This collection is estimated to take 2 becomplete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time volv recurse to expending upon the individual case. Any comments on the amount of time volv recurse to expending upon the individual case. Any comments on the amount of time volv recurse to expending upon the individual case. Any comments on the amount of time volv recurse the six man and containing the complete this form and/or suggestors for recursing this should be sent to the Other Information (E. U.S. Paters and Trademark Office, P.O. Box 1450, Alexandria, VA. 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

R39